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Abstract
Background: Hyperprolactinemia (HPRL) is a classical side effect of antipsychotic drugs primarily attributed to
blockade of dopamine D2 receptors (DRD2s) on the membranes of lactotroph cells within the pituitary gland.
Certain antipsychotic drugs, e.g. risperidone, are more likely to induce HPRL because of relative accumulation within
the adenohypophysis. Nevertheless, due to competition for pituitary DRD2s by high dopamine levels may limit
antipsychotic-induced HPRL. Moreover, the activity of prolactin-producing lactotrophs also depends on other
hormones which are regulated by the extra-pituitary activity of dopamine receptors, dopamine transporters,
enzymes of neurotransmitter metabolism and other factors. Polymorphic variants in the genes coding for these
receptors and proteins can have functional significance and influence on the development of hyperprolactinemia.
Methods: A set of 41 SNPs of genes for dopamine receptors DRD1, DRD2, DRD3, DRD4, the dopamine transporter
SLC6A3 and dopamine catabolizing enzymes MAOA and MAOB was investigated in a population of 446 Caucasians
(221 males/225 females) with a clinical diagnosis of schizophrenia (according to ICD-10: F20) with and without
HPRL who were treated with classical and/or atypical antipsychotic drugs. Additive genetic model was tested and
the analysis was carried out in the total group and in subgroup stratified by the use of risperidone/paliperidone.
Results: One statistically significant association between polymorphic variant rs1799836 of MAOB gene and HPRL in
men was found in the total group. Furthermore, the rs40184 and rs3863145 variants in SLC6A3 gene appeared to be
associated with HPRL in the subgroup of patients using the risperidone/paliperidone, but not with HPRL induced
by other antipsychotic drugs.
(Continued on next page)
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Conclusions: Our results indicate that genetic variants of MAOB and SLC6A3 may have consequences on the
modulation of prolactin secretion. A further search for genetic markers associated with the development of
antipsychotic-related hyperprolactinemia in schizophrenic patients is needed.
Keywords: Dopamine receptors genes, Dopamine transporter SLC6A3, Monoamine oxidase (MAO), Antipsychotics,
Hyperprolactinemia
Background
Schizophrenia is a serious polymorphic mental disorder,
characterized by positive (e.g., hallucinations, delusions),
negative (affective flattening, social withdrawal) and cog-
nitive symptoms (disorders of attention, working mem-
ory deficits). Treatment of schizophrenic illness usually
involves the long-term usage of antipsychotic drugs [1],
which have both therapeutic and side effects, related to
antagonism to D2 receptors. One of the common side
effects of these drugs is hyperprolactinemia [2, 3].
HPRL-related phenomena may lead to additional social
stigmatization of the patient with schizophrenia, which
reduces the compliance of patients to therapy and in-
creases the cost of treatment. HPRL has short- and
long-term consequences that can seriously affect quality
of life: menstrual disturbances, galactorrhea, sexual dys-
function, gynecomastia, infertility, and possibly de-
creased bone mineral density.
Prolactin (PRL) is a polypeptide hormone that contains
199 amino acids and is categorized as part of the growth
hormone family [4]. Prolactin secretion is under a com-
plex neuroendocrine control, in which various agents
participate: neurotransmitters, biologically active neuro-
peptides, hormones of peripheral endocrine glands. Syn-
thesis and secretion of prolactin are carried out by
lactotrophs of the pituitary gland, which constitute an
average of 20–50% of the total cell population of the pi-
tuitary cells [5].
Factors involved in the regulation of prolactin secretion
can be divided into two groups: 1. prolactin-inhibiting –
dopamine (DA), gamma-aminobutyric acid, gastrin, som-
atostatin, gonadotropin-binding protein and 2. prolactin-
stimulating – serotonin, thyrotropin-releasing hormone
(TRH), gonadotropin-releasing hormone (TRG), vaso-in-
testinal peptide, opiates, neurotensin and substance P, oxy-
tocin, angiotensin 2 [6, 7].
Dopamine holds a predominant role in the regula-
tion of prolactin secretion. Dopamine, which is re-
leased by tuberoinfundibular neurons, normally acts
at specific receptors on lactotrophes to tonically in-
hibit prolactin secretion and maintain physiologically
normal prolactin levels in the blood [8]. These dopa-
mine receptors located on lactotroph membranes be-
long to the D2 subclass of the dopamine receptor
family [9, 10].
The hypothalamic dopaminergic neurons, which pro-
vide DA to the anterior pituitary gland, are themselves
regulated by feedback from PRL through a ‘short-loop
feedback mechanism’. Elevation of serum levels of prolac-
tin increases hypothalamic dopamine synthesis [11] and
the concentration of dopamine in hypothalamic-pituitary
portal blood [12].
All typical antipsychotic medications are associated
with sustained hyperprolactinemia due to their high af-
finity for the D2 receptor and their slow dissociation
from the receptor once bound, but the atypicals cloza-
pine and quetiapine differ quite dramatically in their
propensity to cause prolonged high prolactin levels, be-
cause they are loosely bound to D2 receptors [13]. The
dopamine D2 partial receptor agonist aripiprazole is
even capable to reduce prolactin levels [3].
Another way to explain hyperprolactinemia is the abil-
ity of antipsychotic-drugs to cross the blood-brain bar-
rier and to affect the activity of prolactin-inhibiting and
prolactin-stimulating factors. This capacity partly de-
pends upon affinity to the drug efflux transporter
P-glycoprotein, which prevents drugs to pass the
blood brain barrier [14, 15]. This may result in rela-
tively accumulation within the pituitary gland in com-
parison to brain tissue which is protected by the
blood brain barrier [16].
PRL elevations with antipsychotic medication generally
are dose dependent. However, antipsychotics having a
high potential for PRL elevation (amisulpride, sulpriride,
risperidone and paliperidone) can have a profound im-
pact on PRL levels even at relatively low doses, while
PRL levels with antipsychotics having a minimal effect
on PRL, in most cases, can remain unchanged (quetia-
pine) or reduce (aripiprazole) over all dosages. Although
tolerance and decreases in PRL values after long-term
administration of PRL-elevating antipsychotics can
occur, the elevations, in most cases, remain above the
upper limit of normal [3].
In conclusion, antipsychotic drugs may affect prolactin
release directly by blocking dopamine D2 receptors on
lactotrophs, but modulate this activity by affecting dopa-
mine levels within the hypothalamic-pituitary portal
blood. Moreover, antipsychotics can modulate intracere-
bral mechanisms involved in the regulation of prolactin
release. As the main targets for the therapeutic actions
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of neuroleptics in schizophrenia are components of cere-
bral dopamine and – to a lesser extent – serotonin
neurotransmission, the authors aimed at identifying the
association of neuroleptic hyperprolactinemia with poly-
morphism of genes that determine the activity of various
components of dopaminergic transmission – enzymes
that catalyze the synthesis and metabolism of dopamine,
its storage, release into the synaptic cleft and reverse
capture, as well as the structure of its receptors.
According to the literature data genetic variants of
dopaminergic receptors, transporters and enzyme may
have functional consequences on the respond of anti-
psychotic treatment and development of side effects of
therapy.
In the structure of the dopamine receptor D1 (local-
ized on the postsynaptic membrane), two single nucleo-
tide polymorphisms associated with the risk of
developing schizophrenia have been identified: G198A
and G1263A [17]. These substitutions are synonymous,
they do not lead to a change in the amino acid compos-
ition of the receptor, but presumably may have an effect
on gene expression, particularly on the formation of het-
erodimeric forms of the dopamine receptor consisting of
the D1 and D2 subunits [18]. In several studies rs4532
polymorphism in DRD1 is considered as a potential
pharmacogenomic marker for treatment response to
antipsychotic drugs [19, 20].
At least 23 single nucleotide polymorphisms within
DRD2 were evaluated to determine whether any of them
controlled DRD2 expression [21]. The polymorphism of
D2 receptors Taq1A, represented by two alleles – A1
and A2 in the region of the promoter that regulates gene
expression, has been studied most. It was found that re-
duced dopamine D2 receptor binding in the human stri-
atum associated with the A1 allele [22]. The association
of Taq1A polymorphism with schizophrenia was re-
ported [23], it was later shown that A1 allele is associ-
ated with a predisposition to the development of
dyskinesias on the background treatment with neurolep-
tics [24]. The study of this polymorphism is complicated
by the fact that this site is “concurrently” promoted by
another, located next to the gene – ANNK1, which en-
codes protein kinase RKK2. DRD2/ANKK1 genotypes
are associated with susceptibility to second generation
antipsychotic-induced akathisia [25].
Polymorphism of other subtypes of dopamine recep-
tors of the second type, D3 and D4, also, according to a
number of researchers, is associated with a risk of devel-
oping schizophrenia spectrum disorders [26–28]. There
is evidence that the several polymorphic variants in gene
D3 receptor are associated with a risk of developing
schizophrenia [29], as well as with a decrease in the level
of implementation cognitive tasks [30] and antipsychotic
induced tardive dyskinesia [31].
The dopamine transporter gene (SLC6A3) appears to
be one of the most important candidate genes for affect-
ing mental disorders, as it is the target of many psychos-
timulants that cause symptoms similar to the positive
symptoms of schizophrenia. Controversial information
was obtained by studying the effect of polymorphism in
SLC6A3 on pharmacogenetics of adverse events in
schizophrenia treatment [32, 33].
Dopamine can be degraded in several ways, in which
enzymes such as monoamine oxidase (MAO) and
catechol-O-methyltransferase (COMT) play a leading
role. There are two isoforms of monoamine oxidase –
MAOA and MAOB, whose genes are located on the X
chromosome. MAOA catalyzes monoamine neurotrans-
mitters including 5-hydroxytryptamine (5-HT, sero-
tonin), norepinephrine and dopamine, while MAOB
deaminates 2-phenylethylamine and also dopamine [34].
The association of polymorphic variants of the MAOA
gene with features of an alarming series, such as neuroti-
cism and negative affect, is described. Changes in the se-
quence of nucleotides in the promoter region of the
MAOA gene are associated with a reduced level of ex-
pression of this gene and may be associated with an in-
creased level of aggression and impulsivity compared to
a typical MAOA promoter that determines the normal
level of expression [35].
There is a series of studies with the search for associa-
tions of polymorphisms of the genes of dopamine recep-
tors and metabolizing enzymes in various combinations
and response or side effects to antipsychotic therapy:
DRD2 and dopamine transporter SLC6A3 [36]; DRD1,
DRD2, DRD3 and COMT [37]; DRD1, COMT, DRD2,
and DRD3 [38].
Methods
Based upon reviewing the literature we selected a set of
26 polymorphisms in dopamine receptors genes (DRD1,
DRD2, DRD3, DRD4), 12 polymorphic variants of dopa-
mine transporter SLC6A3, as well as 3 polymorphisms of
monoamine oxidase A and B and here we present new
data on the association between them and HPRL in anti-
psychotic drug-treated patients with schizophrenia from
West Siberia, Russian Federation.
Patients
The study population was previous described by Ivanova
et al. [39, 40]. The work was carried out in accordance
with The Code of Ethics of the World Medical Associ-
ation (Declaration of Helsinki 1975, revised in Fortaleza,
Brazil, 2013) for experiments involving humans. The pa-
tients in this study were retrieved from three psychiatric
hospitals in Tomsk, Kemerovo, and Chita oblasts in Si-
beria. The inclusion criteria were a clinical diagnosis of
schizophrenia according to ICD-10 (F20), patients aged
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18–75 years, Caucasian physical appearance and a signed
informed consent form to participate in the study after ap-
proval from the study (protocol N63/7.2014) from the
Local Bioethics Committee of the Mental Health Research
Institute. Exclusion criteria for all patients were
non-Caucasian physical appearance (e.g., Mongoloid, Bur-
yats or Khakassians), pregnancy or relevant gynecological
and endocrine (thyroid) disorders, relevant pharmaco-
logical withdrawal symptoms or organic brain disorders
(e.g., epilepsy, Parkinson’s disease), the presence of acute
and chronic infectious, inflammatory, autoimmune dis-
eases, as well as persons with active oncological diseases,
accompanied by an increased level of prolactin on the
blood.
The total sample consisted of 446 patients (221 males/
225 females). The women were significantly older (p =
2.6e-8, Mann-Whitney test (MWT)) than the men
(mean ± SD 45.2 ± 13.9 vs. 37.8 ± 11.9 years). Among the
women, 86 were > 50 years of age. Women suffered from
the disease for a significantly longer (p = 0.0002, MWT)
period of time (17.6 ± 12.5 vs. 13.1 ± 10.0 years). The me-
dian antipsychotic daily dose was 500 mg CPZeq (quar-
tiles 280; 750) in men and 320 mg CPZeq (quartiles 200;
750) in women (p = 0.0002, MWT).
A total of 227 patients suffered from HPRL (98 males/
129 females) according to the predefined criteria [3, 39].
Demographic and clinical features of patients with
schizophrenia with and without hyperprolactinemia are
presented in Table 1.
One hundred ninety-one patients were treated with
conventional antipsychotics in oral and/or long-acting
formulations. The most common conventional anti-
psychotic was haloperidol, which was used in 110 patients,
but other treatments included oral chlorpromazine, chlor-
prothixene, trifluoperazin, and zuclopenthixol, and/or
long-acting formulations of haloperidol-, zuclopenthixol-,
and flupenthixol-decanoate. A total of 176 patients were
treated with atypical antipsychotics: risperidone, clozapine,
quetiapine, olanzapine, amisulpride, paliperidone, and ser-
tindole. Different combinations of classical and atypical
drugs were used by 79 patients. 76 patients were treated
with risperidone/paliperidone.
To compare antipsychotic medications, all dosages were
converted into chlorpromazine equivalents (CPZeq) [41].
Blood samples were taken 8 h after overnight fasting in
tubes containing EDTA for DNA extraction and in tubes
with CAT (clot activator) to obtain serum (BD Vacutai-
ner). Blood with EDTA was stored in several aliquots at
-20 °C until DNA isolation. Blood samples with CAT
were centrifuged for 30 min at 1500 rpm at 4 °C to ob-
tain serum.
Hormone analysis
The PRL concentration was measured in serum using the
AccuBind ELISA Microwells kit (Monobind Inc., USA). In
this microplate immunoenzymatic assay, the ELISA has a
sensitivity of 0.004 ng/well. This is equivalent to a sample
containing 0.150 ng/ml PRL. The upper limits for normal
PRL concentration were set at ≤20 ng/ml for men and ≤
25 ng/ml for non-pregnant, non-nursing women [39, 40].
For women of reproductive age, blood was when possibly
taken in the follicular phase of the menstrual cycle. This
corresponds to the criteria for HPRL applied by Kelly et
al. [42] and Peuskens et al. [3].
DNA analysis
DNA was isolated from the leukocytes in whole periph-
eral blood from patients with mental disorders using the
standard phenol-chloroform method.
Genotyping was carried out for DRD1, DRD2, DRD3,
DRD4, and SLC6A3 genes in the Genome Analysis Facil-
ity, Dept. Genetics (Head: Prof. Dr. C. Wijmenga), Uni-
versity Medical Center Groningen on the MassARRAY®
Analyzer 4 (Agena Bioscience™) using the set SEQUE-
NOM Consumables iPLEX Gold 384. DNA sample
preparation for SEQUENOM MassARRAY® Analyzer 4
includes several steps: a standard PCR reaction to obtain
the amplification products, a shrimp alkaline phosphat-
ase (SAP) reaction to neutralize the unincorporated
dNTPs in the amplification products, the PCR iPLEX
Gold extension reaction, and then placing the samples
on a special chip (SpectroCHIP Array) using NanoDispen-
ser RS1000 prior to loading them into the analyzer. SNPs
in MAOA, MAOB genes were genotyped in the Mental
Health Research Institute, Tomsk National Research Med-
ical Center of the Russian Academy of Sciences, using the
fluorogenic 5′-exonuclease TaqMan technology per-
formed on the real-time polymerase chain reaction system
“StepOnePlus” (Applied Biosystems, USA).
We selected a set of 26 SNPs from the following dopa-
mine receptors genes: DRD1, DRD2, DRD3, DRD4
(Table 2), 12 polymorphic variants of dopamine transporter
Table 1 Demographic and clinical features of patients with schizophrenia with and without HPRL
Feature Patients with HPRL, n = 227 Patients without HPRL, n = 219 p-value
Age 49.19 ± 13.19 42.94 ± 13.56 0.031
Male/Female 98/129 123/96 0.006
Dose of antipsychotics into chlorpromazine equivalent 400 (225; 750) 400 (280; 750) 0.074
Duration of the disease 11.0 (4.0; 22.0) 14.0 (8.0; 22.0) 0.041
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SLC6A3 and 3 polymorphisms of genesMAOA andMAOB
(Table 3).
Statistical analysis
We analyzed associations between the polymorphisms
and HPRL using logistic regression models including
HPRL as a dependent categorical variable and polymor-
phisms as the predictors. Age, sex, and CPZeq were used
as covariates. Additive genetic model was tested and
Odds ratios (OR) along with 95% confidence intervals
(CI) were calculated regarding the risk of HPRL for the
rare allele vs common allele. Prior to the analysis, the
polymorphisms were filtered out in case of minor allele
frequency below 5% or Hardy-Weinberg equilibrium
(HWE) p-value below 0.001. HWE was tested using
Fisher’s exact test except for SNPs located in the
X-chromosomal (MAOA, MAOB). The Mann-Whitney
test was used to compare qualitative traits and χ2 test
for categorical traits.
All calculations were performed in the R statistical en-
vironment using basic R functions and the SNPassoc
package [43].
Results
From the list of 38 SNPs studied of dopamine receptor
genes and SLC6A3 genes we excluded 4 SNPs (rs6275,
rs6347, rs2550956, rs11133767) with Hardy-Weinberg
equilibrium p-value < 0.001, thus leaving 34 SNPs for
the analysis of associations with HPRL. In the total
group of patients none of the studied genetic markers
localized in autosomal chromosomes are associated with
HPRL (Additional file 1).
Polymorphic variants of monoamine oxidase genes are
localized in the X chromosome. Taking into account the
hemizygotic status of X-chromosomal markers for men,
the analysis of these markers was carried out separately
in men and women. Using the logistic regression ana-
lysis with age and CPZeq as covariate we found the asso-
ciation of rs1799836 with HPRL in men (Table 4). Allele
Table 2 List of analyzed polymorphic variants of dopamine receptor genes
Gene SNP Chromosome Chromosome position Alleles Minor Allele Frequency
DRD1 rs4532 5 174,870,150 T/C 24.4
DRD2 rs6275 11 113,283,477 C/T 47.3
DRD2 rs6277 11 113,283,459 C/T 24.4
DRD2 rs1076560 11 113,283,688 C/A 22.9
DRD2 rs1801028 11 113,283,484 C/G 3.1
DRD2 rs4245147 11 113,318,007 T/C 45.4
DRD2 rs2283265 11 113,285,536 G/T 22.7
DRD2 rs6279 11 113,281,073 G/C 47.8
DRD2 rs1076562 11 113,296,008 G/A 42.1
DRD2 rs2734842 11 113,280,274 G/C 46.7
DRD2/ANKK1 rs2734849 11 113,270,160 T/C 24.5
DRD3 rs11721264 3 113,879,404 G/A 41.4
DRD3 rs167770 3 113,879,562 A/G 42.2
DRD3 rs3773678 3 113,870,078 C/T 32.0
DRD3 rs963468 3 113,862,887 G/A 27.2
DRD3 rs7633291 3 113,887,068 T/G 22.4
DRD3 rs2134655 3 113,858,201 G/A 20.3
DRD3 rs9817063 3 113,847,108 C/T 42.8
DRD3 rs324035 3 113,868,854 C/A 40.2
DRD3 rs1800828 3 113,891,549 G/C 22.2
DRD3 rs167771 3 113,876,275 A/G 41.1
DRD3 rs6280 3 113,890,815 T/C 48.6
DRD3 rs1587756 3 113,902,751 T/C 14.6
DRD4 rs3758653 11 636,399 T/C 24.7
DRD4 rs11246226 11 641,191 A/C 47.7
DRD4 rs936461 11 636,496 G/A 45.7
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and genotype frequencies are shown in Additional file 2.
A protective effect of the rs1799836*A allele against
HPRL development was observed.
Due to the fact that according to literature data, HPRL
is significantly more common in patients receiving risperi-
done/paliperidone, the next step was the analysis in the
subgroup of patients using the risperidone/paliperidone.
Using logistic regression with age, gender, and CPZeq as
covariates we found that the rs40184 and rs3863145 vari-
ants in SLC6A3 gene appeared to be associated with
HPRL in this subgroup of patients (Table 5). Allele and
genotype frequencies are shown in Additional file 3. The
rs40184*A and the rs3863145*C alleles were found to ex-
hibit a protective effect, reducing the risk of hyperprolacti-
nemia in carriers of these genotypes. Notably, the both
SNPs are in some linkage disequilibrium LD, therefore,
their association with the HPRL is bound by the same
haplotype (Additional file 4). Polymorphisms in MAO
genes were not associated with hyperprolactinemia in the
studied subgroup (Additional file 5).
Discussion
We studied the association between polymorphisms of
genes relevant for dopaminergic neurotransmission such
as receptors, transporter, and enzymes with anti-
psychotic drug-induced HPRL in white patients with
schizophrenia from Siberia. We excluded patients with
physiological or pathological conditions that may affect
PRL secretion and corrected for variables related to PRL
secretion and/or that may determine antipsychotic drug
load. The assessment of a possible association is consid-
ered the first step in discovering the possible functional
consequences of genetic variations. We distinguished
HPRL for men and women. The studied women were
significantly older than the men and patients with HPRL
were more often female than those without. Premeno-
pausal women have significantly higher PRL levels than
postmenopausal female persons, who have not signifi-
cantly different levels in comparison to men [44–46].
This might be related to modulation of PRL dynamics
by estrogen levels [44]. The gender and age differences
between the patients with and without HPRL may have
falsely decreased the actual prevalence of drug-induced
HPRL in the HPRL group in comparison to non-HPRL
patients. However, when only male patients were studied
significant association was found with one polymorph-
ism rs1799836 of MAOB gene.
MAOB, located adjacent to MAOA on the opposite
strand at chromosome Xp11.23, is involved in the break-
down of dopamine in the brain [34]. MAO-B is widely
Table 3 List of analyzed polymorphic variants of the dopamine transporter gene and the monoamine oxidase genes
Gene SNP Chromosome Chromosome position Alleles Minor Allele Frequency
SLC6A3 rs3756450 5 1,448,148 T/C 34.9
SLC6A3 rs2550956 5 1,447,841 T/C 17.3
SLC6A3 rs6347 5 1,411,412 A/G 29.8
SLC6A3 rs2617605 5 1,442,521 A/G 25.6
SLC6A3 rs3863145 5 1,392,711 C/T 16.8
SLC6A3 rs250686 5 1,425,159 G/A 40.7
SLC6A3 rs464049 5 1,423,905 C/T 39.1
SLC6A3 rs4975646 5 1,433,401 G/A 13.4
SLC6A3 rs1048953 5 1,438,174 C/T 14.6
SLC6A3 rs11133767 5 1,401,580 A/G 31.8
SLC6A3 rs27048 5 1,412,645 C/T 32.1
SLC6A3 rs40184 5 1,395,077 G/A 41.3
МАОА rs6323 X 43,591,036 G/T 37.5
МАОА rs1137070 X 43,603,391 C/T 44.8
МАОB rs1799836 X 43,627,999 A/G 45.6
Table 4 Analysis of association between HPRL and the
polymorphisms of MAO genes for all patients divided by gender
Gender SNP OR 95% CI
Lower bound
95% CI
Upper bound
p-value
Females rs1799836 0.939 0.644 1.369 0.744
rs1137070 0.757 0.497 1.153 0.195
rs6323 0.786 0.512 1.208 0.273
Males rs1799836 0.748 0.561 0.998 0.048*
rs1137070 1.279 0.942 1.737 0.115
rs6323 1.315 0.970 1.782 0.078
Logistic regression analysis was used to test additive genetic model for
association between HPRL and the MAO genes polymorphisms in males and
females separately adjusting for age and CPZeq. OR – odds ratio; CI – lower
and upper bound 95% confidence intervals. ORs are reported for the risk of
HPRL attributable to the rare allele vs common allele
*Values are deemed to have significance
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distributed within the brain with moderate levels within
the adenohypophysis – where MAO-A is low – and
hypothalamus [47, 48]. A non-coding single nucleotide
polymorphism rs1799836 in intron 13 is associated with
Parkinson’s disease [49, 50], schizophrenia [51] and is
also significantly associated with reduced negative
emotionality [52]. Further, a case-control study by Gasso
et al. indicates that the G allele is a risk factor for devel-
oping schizophrenia in a Spanish population [53].
Kang S.G. et al., reported that males schizophrenic pa-
tients with MAOA 3-repeat uVNTR and MAOB A644
genotype has higher association with antipsychotic-induced
restless leg syndrome [54].
A. C. Need et al. (2006) studied whether obesity is as-
sociated with genetic variants that increase the availabil-
ity of dopamine. Low activity genotypes at both the
MAOA and MAOB loci – showed a relative risk for
obesity of 5.01 [55]. Antipsychotic-induced weight gain,
including as a consequence of increasing the level of
prolactin, can be a particular problem of in schizophre-
nia treatment, often causing non-compliance and conse-
quent relapse. It is possible that functional variants in
the MAOA and MAOB genes could predispose to
antipsychotic-induced weight gain in patients with
schizophrenia.
Our preliminary hypothesis was that genetic variants
of dopamine receptors may have functional conse-
quences on the modulation of PRL secretion and may
play an important role in the development of hyperpro-
lactinemia, but the results of the study indicate that
there is no association in the group of patients.
However we found that rs40184 and rs3863145 of
SLC6A3 gene are associated with risperidone/paliperi-
done induced HPRL, but not with HPRL induced by
other antipsychotic drugs. The solute carrier family 6
(neurotransmitter transporter), member 3 (SLC6A3)
gene encodes the dopamine transporter DAT. The differ-
ence between risperidone/paliperidone and other anti-
psychotics might indicate that, although dopamine
transporters are present within the adenohypophysis
[56] and may have a role in prolactin secretion [57], the
pharmacological mechanism related to this association is
less likely on the level of the pituitary gland (which is
outside the blood-brain-barrier) but localized within the
brain itself. Risperidon/paliperidone relatively accumu-
lates within the pituitary gland in comparison to other
antipsychotics [16] and thus can be expected to bind to
a higher extend to dopamine D2 receptors there.
The DAT protein is expressed in the membrane of
neurons, where it transports dopamine from the synaptic
cleft back into neurons for reuse. SLC6A3 plays a critical
role in controlling dopamine transmission (spatial and
temporal domains) through the accumulation of dopa-
mine in extracellular space which is major site of action
of psychostimulant drugs [58–60]. The results of several
studies indicate that altered SLC6A3 functioning may
lead to inter-individual variability of response to anti-
psychotic drug treatment. Sjoholm H. et al. (2004) [61]
reported increased number of SLC6A3 binding sites in
the schizophrenia patients who were being treated with
Table 5 Analysis of association between HPRL and the genetic
polymorphisms in patients from risperidone/paliperidone group
Gene SNP OR 95% CI
Lower bound
95% CI
Upper bound
p-value
DRD1 rs4532 0.522 0.216 1.261 0.148
DRD2 rs1076562 0.490 0.192 1.249 0.135
DRD2 rs4245147 1.148 0.519 2.541 0.733
DRD2 rs2283265 0.900 0.301 2.686 0.850
DRD2 rs2734842 0.472 0.187 1.194 0.113
DRD2 rs6277 2.081 0.864 5.011 0.102
DRD2 rs6279 0.434 0.164 1.145 0.092
DRD2 rs1076560 0.969 0.327 2.878 0.955
DRD2/ANKK1 rs2734849 1.833 0.781 4.302 0.164
DRD3 rs11721264 2.042 0.677 6.156 0.205
DRD3 rs2134655 0.659 0.203 2.140 0.488
DRD3 rs963468 0.647 0.251 1.666 0.367
DRD3 rs167771 1.150 0.244 5.414 0.859
DRD3 rs324035 1.719 0.380 7.783 0.482
DRD3 rs167770 1.963 0.622 6.195 0.250
DRD3 rs7633291 2.462 0.640 9.473 0.190
DRD3 rs9817063 1.635 0.626 4.270 0.316
DRD3 rs1587756 2.407 0.489 11.861 0.280
DRD3 rs1800828 2.813 0.739 10.711 0.129
DRD3 rs3773678 1.556 0.326 7.412 0.579
DRD3 rs6280 2.153 0.668 6.947 0.199
DRD4 rs3758653 1.403 0.410 4.806 0.590
DRD4 rs936461 1.500 0.577 3.895 0.405
DRD4 rs11246226 2.421 0.955 6.142 0.063
SLC6A3 rs27048 1.419 0.660 3.054 0.370
SLC6A3 rs3756450 1.373 0.512 3.684 0.529
SLC6A3 rs40184 0.341 0.137 0.852 0.021*
SLC6A3 rs4975646 0.640 0.258 1.589 0.336
SLC6A3 rs2617605 0.880 0.337 2.299 0.794
SLC6A3 rs464049 0.538 0.209 1.384 0.199
SLC6A3 rs1048953 0.823 0.337 2.008 0.668
SLC6A3 rs250686 0.563 0.214 1.482 0.245
SLC6A3 rs3863145 0.362 0.135 0.970 0.043*
Logistic regression analysis was used to test an additive genetic model for
association between HPRL and the polymorphisms in adjusting for age, sex
and CPZeq. OR – odds ratio; CI – lower and upper bound 95% confidence
intervals. ORs are reported for the risk of HPRL attributable to the rare allele vs
common allele
*Values are deemed to have significance
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dopamine D2-receptor blocking antipsychotics. Single
locus analysis showed significant association of nine vari-
ants from SLC6A3, PIP4K2A and BDNF genes with in-
complete antipsychotic response in schizophrenia patients
with high severity [62]. The multifactor-dimensionality re-
duction approach identified gene-gene interaction among
BDNF_rs7103411-BDNF_rs1491851-SLC6A3_rs40184 in
severely ill incomplete responders [62]. Hence, at least
some intracerebral pharmacological effects of altered
SCL6A3 functioning can be expected and these may also
influence PRL secretion.
Our new data could be taken into account when ther-
apy with risperidone/paliperidone or different anti-
psychotic therapy is considered regarding the risk of
developing HPRL.
Conclusions
In conclusion, we found an association of
antipsychotic-induced HPRL with rs1799836 of the
MAOB gene in (hemizygous) men and rs40184 and
rs3863145 variants in the SLC6A3 gene which codes for
the dopamine transporter in patients using risperidone/
paliperidone. Strength of our study is the relatively large
patient population and careful assessment of hyperpro-
lactinemia. A relative weakness is the sex difference be-
tween the HPRL versus non-HPRL groups and the
relatively high age of women as this may increase the
number of post-menopausal women in the HPRL-group.
However, this also makes the associations which we found
more likely to exist. A further search for genetic markers
associated with the development of antipsychotic-related
hyperprolactinemia in schizophrenic patients is needed.
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